Novo Nordisk challenges Eli Lilly ads in lawsuit

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of misleading advertising related to obesity drugs in the U.S. market. The dispute centers on Lilly’s claims about weight loss effectiveness, which Novo argues are based on outdated or incorrect dosing comparisons. Novo is seeking to stop Lilly’s ads and recover damages, following allegations of false advertising under U.S. laws.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل